Navigation Links
Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
Date:1/26/2009

FAIRFIELD, N.J., Jan. 26 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company has entered into a Distributor Agreement with Perrigo Company (Nasdaq: PRGO), a leading manufacturer in the generic prescription marketplace, designating Perrigo as the Exclusive Authorized Distributor of generic versions of Medimetriks' branded products in the U.S. The agreement calls for Medimetriks to receive a percentage of Perrigo's Net Sales on the non-branded products, allowing Medimetriks to maximize its investment in its brands and maintain a revenue stream from the markets these brands create.

Founded in May, 2008, Medimetriks launched its first prescription brands in the 4th Quarter of 2008 to the Dermatology and Podiatry markets. These brands include Pacnex(TM) (7% Benzoyl Peroxide) Wash, a topical treatment for acne in a unique vehicle containing Aloe and Green Tea; Sumaxin(TM) (Sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads, a topical treatment for acne and rosacea also in a vehicle containing Aloe and Green Tea; and Uramaxin(TM) (45% Urea) Nail Gel, a treatment for diseased and damaged nails in a unique vehicle containing Menthol, Camphor and Eucalyptus Oil. The agreement also includes future products launched by Medimetriks.

"Our agreement with Perrigo represents a strategic opportunity for Medimetriks to leverage our brand assets in the non-branded marketplace," stated Bradley Glassman, President and CEO of Medimetriks. "We are pleased to work with one of the world's leading healthcare manufacturers and generic marketers, with a particular expertise in the topical generic market."

"We believe our relationship with Medimetriks will be a mutually beneficial one," stated Sharon Kochan, Executive Vice President of Perrigo. "Medimetriks' Management Team, having previously built Bradley Pharmaceuticals into an approximately $200 million gross revenue company, has a solid track record of success in building a branded pharmaceutical business in the markets they serve."

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.

Pacnex(TM) Wash is for external use only. Avoid contact with eyes, lips or mucous membranes. If severe irritation develops, discontinue use of Pacnex(TM) Wash. While using Pacnex(TM) Wash, patients should be advised to avoid unnecessary sun exposure. Please see full Prescribing Information available at www.medimetriks.com.

Sumaxin(TM) Cleansing Pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or sulfur. Sumaxin(TM) Cleansing Pads are not to be used by patients with kidney disease. Although rare, topical sodium sulfacetamide may cause local irritation. Please see full Prescribing Information available at www.medimetriks.com.

Uramaxin(TM) Nail Gel is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappear on discontinuing the medication. Use as directed. Please see full Prescribing Information available at www.medimetriks.com.


'/>"/>
SOURCE Medimetriks Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
2. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
3. Perrigo Announces FDA Final Approval for Ibuprofen PM
4. Perrigo Settles Desloratadine Patent Litigation
5. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
6. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
7. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
8. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
9. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
10. Perrigo Company Announces Appointment of New Board Member
11. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... VA (PRWEB) , ... August 23, 2017 , ... The Stevie® Awards have announced the ... Business Awards , the world’s premier business awards competition. , Nominees in the 2017 IBAs ... determined by a points system based on the total number of awards won in the ...
(Date:8/23/2017)... ... August 23, 2017 , ... Boling ... returned home to Indiana, and is now seeing patients at Boling Vision Center’s ... specializes in the diagnosis and treatment of eye disease, medical retina, high-technology cataract ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... Academy of Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is ... injury. According to the report, a wider scope of physical therapy options is ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western ... spoke at a popular international aesthetics conference for medical professionals about the positive ... patients’ health and his growing practice. , Dr. George K. Ibrahim ...
(Date:8/22/2017)... ... ... Glass is new to the Texas market, but is proudly managed by widely recognized All ... models, in Grand Prairie, TX, located in the center of the DFW Metroplex, the fourth ... for the past 40 years with 32 convenient locations in Texas, Nevada and California resulting ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
Breaking Medicine Technology: